Boston Scientific Begins AVANT GUARD Clinical Trial To Evaluate FARAPULSE Pulsed Field Ablation System As First-Line Treatment For Persistent Atrial Fibrillation

Boston Scientific Corporation -1.12%

Boston Scientific Corporation

BSX

68.07

-1.12%

The randomized AVANT GUARD trial will enroll more than 500 patients diagnosed with persistent AF at up to 75 sites globally. The company now anticipates U.S. Food and Drug Administration approval of the FARAPULSE PFA System in the first quarter of 2024. 

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via